StreetInsider.com News Articles

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

Tue, 08 Sep 2026 07:00:00 -0400

WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the management team will participate in three upcoming investor conferences in September 2026.

Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Company Presentation
Presenter: Jonathan Javitt, M.D., M.P.H., Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals
Location: New York, New York
Date: September 9, 2026
Presentation Time: 9:35-9:55 a.m. ET

2026 Cantor Global Healthcare Conference
Fireside Chat
Presenter: Jonathan Javitt, M.D., M.P.H., Founder, Chairman and Chief Executive Officer

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

Tue, 08 Sep 2026 07:00:00 -0400

2026 Cantor Global Healthcare Conference
Fireside Chat
Presenter: Jonathan Javitt, M.D., M.P.H., Founder, Chairman and Chief Executive Officer

H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)

Wed, 26 Aug 2026 06:43:38 -0400

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating and $45.00 price target on NRx Pharmaceuticals, Inc. (NASDAQ: NRXP).

The analyst commented: "In 2Q26, NRx's pipeline progressed across the KETAFREE abbreviated new drug application (ANDA), the branded NRX-100 new drug application (NDA), NRX-101, HOPE Therapeutics, and the GeNeuro and NRx Defense Systems subsidiaries formed during the quarter. Importantly, NRx worked with the FDA to resolve the manufacturing issue with the luer lock vial used for both KETAFREE and NRX-100; management continues to target a KETAFREE 2026 approval and first commercial sales, while the NRX-100 NDA is poised to finalize in 3Q26

Form 8-K NRX Pharmaceuticals, For: Aug 17

Mon, 17 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260817/26935083.html

Form 8-K NRX Pharmaceuticals, For: Aug 17

Mon, 17 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260817/26935083.html

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

Mon, 17 Aug 2026 07:00:00 -0400

Key recent and second quarter highlights include:

Completed first-cycle FDA review of the Company’s ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item, a manufacturer's attestation on the vial, has been submitted to FDA.
Initiation of commercial scale manufacturing of preservative-free ketamine building to launch stock of 5 million doses to be ready for commercialization in 2026.
Selected by the Defense Advanced Research Projects Agency (DARPA) as prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of NRX-101 with robotic TMS. Anticipated non-dilutive funding exceeds $11.5 million, subject to

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

Mon, 17 Aug 2026 07:00:00 -0400

Key recent and second quarter highlights include:

Completed first-cycle FDA review of the Company’s ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item, a manufacturer's attestation on the vial, has been submitted to FDA.
Initiation of commercial scale manufacturing of preservative-free ketamine building to launch stock of 5 million doses to be ready for commercialization in 2026.
Selected by the Defense Advanced Research Projects Agency (DARPA) as prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of NRX-101 with robotic TMS. Anticipated non-dilutive funding exceeds $11.5 million, subject to

Form 10-Q NRX Pharmaceuticals, For: Jun 30

Fri, 14 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260814/26931715.html

Form 10-Q NRX Pharmaceuticals, For: Jun 30

Fri, 14 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260814/26931715.html

H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)

Mon, 10 Aug 2026 06:50:18 -0400

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating and $45.00 price target on NRx Pharmaceuticals, Inc. (NASDAQ: NRXP).

The analyst commented: "This morning, NRx disclosed that FDA completed first-cycle review of the KETAFREE abbreviated New Drug Application (ANDA) for preservative-free IV ketamine with no major deficiencies related to the drug components of the product, and no new clinical, safety, efficacy, or drug-related data required. The one open item is a major deficiency tied to the twist-off cap of the luer lock vial — classified as major only because it affects the container closure — which FDA has now scoped down

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

Fri, 07 Aug 2026 16:01:00 -0400

Conference Call 8:30 a.m. ET, Monday, August 10, 2026

MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss the FDA's completion of first-cycle review of the Company's ANDA for preservative-free ketamine, announced earlier today.

Participating on the call will be Jonathan Javitt, MD, MPH, Founder and Chief Executive Officer; Glenn Tyson, Chief Commercial Officer; and Chaim Hurvitz, Director, former director of Teva and

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

Fri, 07 Aug 2026 16:01:00 -0400

Conference Call 8:30 a.m. ET, Monday, August 10, 2026

Participating on the call will be Jonathan Javitt, MD, MPH, Founder and Chief Executive Officer; Glenn Tyson, Chief Commercial Officer; and Chaim Hurvitz, Director, former director of Teva and

FDA completes first-cycle review of NRx ketamine ANDA with packaging query

Fri, 07 Aug 2026 07:01:34 -0400

NRx Pharmaceuticals (NASDAQ: NRXP) announced that the FDA has completed its first-cycle review of the company's Abbreviated New Drug Application (ANDA) for preservative-free ketamine, finding no major deficiencies related to the drug product, its ingredients, proposed labeling, or Chemistry, Manufacturing and Controls matters.

The FDA identified one remaining item classified as a major deficiency due to its relation to the product's container closure system — specifically, a question about whether the luer lock tip of the medication vial would perform properly when connected to a syringe. The company says the same luer lock vial is already used in three currently FDA-approved

FDA completes first-cycle review of NRx ketamine ANDA with packaging query

Fri, 07 Aug 2026 07:01:34 -0400

Form 8-K NRX Pharmaceuticals, For: Aug 07

Fri, 07 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260807/26887333.html

Form 8-K NRX Pharmaceuticals, For: Aug 07

Fri, 07 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260807/26887333.html

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

Fri, 07 Aug 2026 07:00:00 -0400

FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters.
Remaining item relates to manufacturer certification for a luer lock vial already used in three FDA-approved ANDA products with 11.9 million units shipped over the past 12 months without complaints, returns, adverse events, or recalls.
No new clinical, safety, efficacy, or drug-related data are required for ANDA approval.
Following an August 6, 2026 clarification meeting attended by senior FDA leadership, FDA committed to reviewing the requested certification in the shortest possible review cycle.
NRX believes completion of first-cycle

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

Fri, 07 Aug 2026 07:00:00 -0400

FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters.
Remaining item relates to manufacturer certification for a luer lock vial already used in three FDA-approved ANDA products with 11.9 million units shipped over the past 12 months without complaints, returns, adverse events, or recalls.
No new clinical, safety, efficacy, or drug-related data are required for ANDA approval.
Following an August 6, 2026 clarification meeting attended by senior FDA leadership, FDA committed to reviewing the requested certification in the shortest possible review cycle.
NRX believes completion of first-cycle

Form 8-K NRX Pharmaceuticals, For: Jul 21

Wed, 22 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260722/26798048.html

Form 8-K NRX Pharmaceuticals, For: Jul 21

Wed, 22 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260722/26798048.html

New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.